Following a regulatory approval, shares of Tempus AI, Inc. (NASDAQ: TEM) are experiencing a notable surge on the stock charts today. As of the latest market update, TEM stock had climbed 7.72%, reaching $33.21. This increase reflects investor optimism following the company’s significant milestone.
Regulatory Milestone For Tempus ECG-AF Device
By receiving the FDA’s 510(k) approval for its Tempus ECG-AF device, Tempus AI (TEM) reached a significant regulatory milestone. Using artificial intelligence, this novel technology determines whether patients are most susceptible to atrial fibrillation/flutter (AF).
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
Interestingly, this clearance is the first time that an AF indication has been approved by the FDA in the category of “cardiovascular machine learning-based notification software,” allowing doctors to use this innovative algorithm in patient treatment. Millions of people suffer with atrial fibrillation, a common cause of stroke that presents diagnostic difficulties.
The FDA’s approval of Tempus AI’s groundbreaking method to delivering AI-driven healthcare solutions, which enables early detection of cardiovascular illnesses and disorders, is highlighted by this. The Tempus ECG-AF is the initial offering in a series of next-generation diagnostics designed to detect patients at risk for various cardiovascular issues.
Implications For Clinical Practice
The clearance of the Tempus ECG-AF device enhances the company’s capability to support clinicians in identifying patients earlier, potentially leading to more effective treatments. The algorithm is designed to analyze recordings from 12-lead electrocardiogram (ECG) devices, identifying signs indicative of AF risk within the subsequent 12 months.
Comparable Initiatives
Additionally, Tempus previously established a new partnership with United Therapeutics (UT), a preeminent biotechnology business dedicated to giving patients a better future via the creation of cutting-edge medical products and innovations. Tempus will research and develop AI-based medical device software to identify individuals who may be undiagnosed with pulmonary hypertension (PH) as part of this partnership.
The company’s AI-enabled care pathway intelligence solution, Tempus Next, will be utilized by Tempus’ research and development program to help with the algorithm’s implementation at participating facilities. In a prospective clinical research at up to 60 locations, clinicians will assess its capacity to identify individuals at risk of undiagnosed PH and to monitor the clinical outcomes of patients who are flagged for further examination.
